You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 5, 2024

~ Buy the STIVARGA (regorafenib) Drug Profile, 2024 PDF Report in the Report Store ~

STIVARGA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Stivarga patents expire, and when can generic versions of Stivarga launch?

Stivarga is a drug marketed by Bayer Hlthcare and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and sixty-seven patent family members in forty-eight countries.

The generic ingredient in STIVARGA is regorafenib. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the regorafenib profile page.

DrugPatentWatch® Generic Entry Outlook for Stivarga

Stivarga was eligible for patent challenges on September 27, 2016.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 8, 2031. This may change due to patent challenges or generic licensing.

There have been eight patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for STIVARGA?
  • What are the global sales for STIVARGA?
  • What is Average Wholesale Price for STIVARGA?
Drug patent expirations by year for STIVARGA
Drug Prices for STIVARGA

See drug prices for STIVARGA

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for STIVARGA
Generic Entry Date for STIVARGA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for STIVARGA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Great Novel Therapeutics Biotech & Medicals CorporationPhase 1/Phase 2
Anshan Tumor HospitalPhase 1/Phase 2
University of MiamiPhase 2

See all STIVARGA clinical trials

Paragraph IV (Patent) Challenges for STIVARGA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
STIVARGA Tablets regorafenib 40 mg 203085 2 2016-09-27

US Patents and Regulatory Information for STIVARGA

STIVARGA is protected by four US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of STIVARGA is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting STIVARGA

Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Treatment of cancers with acquired resistance to kit inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR (GIST), INCLUDING BUT NOT LIMITED TO PATIENTS PREVIOUSLY TREATED WITH IMATINIB AND PATIENTS WITH GIST HAVING RESISTANCE TO A KIT TYROSINE KINASE INHIBITOR

Process for the preparation of 4-{4-[({[4 chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorphenoxy-N-- ethylpyridie-carboxamide, its salts and monohydrate
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenox- y]-N-methylpyridine-2-carboxamide monohydrate
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

FDA Regulatory Exclusivity protecting STIVARGA

TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC OR LIVER CANCER) WHO HAVE BEEN PREVIOUSLY TREATED WITH THE DRUG SORAFENIB.
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare STIVARGA regorafenib TABLET;ORAL 203085-001 Sep 27, 2012 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Bayer Hlthcare STIVARGA regorafenib TABLET;ORAL 203085-001 Sep 27, 2012 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Bayer Hlthcare STIVARGA regorafenib TABLET;ORAL 203085-001 Sep 27, 2012 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Bayer Hlthcare STIVARGA regorafenib TABLET;ORAL 203085-001 Sep 27, 2012 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Bayer Hlthcare STIVARGA regorafenib TABLET;ORAL 203085-001 Sep 27, 2012 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for STIVARGA

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Bayer Pharma AG Stivarga regorafenib EMEA/H/C/002573
Stivarga is indicated as monotherapy for the treatment of adult patients with:metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies - these include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy;unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib;hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
Authorised no no no 2013-08-26
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for STIVARGA

When does loss-of-exclusivity occur for STIVARGA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 1060
Patent: PROCEDIMIENTO PARA PREPARAR 4-{4-[({[4-CLORO-3-(TRIFLUOROMETIL)FENIL]AMINO}CARBONIL)AMINO]-3-FLUOROFENOXI}-N-METILPIRIDIN-2-CARBOXAMIDA
Estimated Expiration: ⤷  Sign Up

Patent: 6395
Patent: 4-{4-[({[4-CLORO-3-(TRIFLUOROMETIL)FENIL]AMINO}CARBONIL)AMINO]-3-FLUOROFENOXI}-N-METILPIRIDIN-2-CARBOXAMIDA, SU MONOHIDRATO O SAL EN UNA FORMA DE PUREZA ALTA
Estimated Expiration: ⤷  Sign Up

Australia

Patent: 11240113
Patent: Process for the preparation of 4- {4-[({[4 -chloro-3 -(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorophenoxy}-N-methylpyridine-2-carboxamide, its salts and monohydrate
Estimated Expiration: ⤷  Sign Up

Brazil

Patent: 2012026117
Patent: processo para preparação de 4-{4-[({[4-cloro-3-(triflúor-metil)fenil]amino}carbonil)amino]-3-flúor-fenóxi}-n-metil-piridina-2-carboxamida, seus sais e monohidrato
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 96238
Patent: PROCEDE DE PREPARATION DE 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)-PHENYL]AMINO}CARBONYL)AMINO]-3-FLUOROPHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE, SES SELS ET SON MONOHYDRATE (PROCESS FOR THE PREPARATION OF 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)- PHENYL]AMINO}CARBONYL)AMINO]-3-FLUOROPHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE, ITS SALTS AND MONOHYDRATE)
Estimated Expiration: ⤷  Sign Up

Chile

Patent: 12002840
Patent: Procedimiento de preparacion del compuesto de fórmula (i) 4-(4-((((4-cloro-3-(trifluorometil)fenil)amino)carbonil)amino)-3-fluorofenoxi)-n-metilpiridina-2-carboxamida y sus sales a partir de 4-(4-amino-3-fluorofenoxi)-n-metilpiridina-2-carboxamida y 1-cloro-4-isocianato-2-(trifluorometil)benceno; y el compuesto de fórmula (i).
Estimated Expiration: ⤷  Sign Up

China

Patent: 2947271
Patent: Process for the preparation of 4- {4-[({[4 -chloro-3 -(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorophenoxy}-n-methylpyridine-2-carboxamide, its salts and monohydrate
Estimated Expiration: ⤷  Sign Up

Patent: 3980191
Patent: Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorophenoxy}-N-methylpyridine-2-carboxamide, its salts and monohydrate
Estimated Expiration: ⤷  Sign Up

Colombia

Patent: 30136
Patent: Procedimiento para la preparación de 4-{4[({4-cloro-3-(trifluorometil) fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridina-2-carbocamida, sus sales y su monohidrato
Estimated Expiration: ⤷  Sign Up

Costa Rica

Patent: 120526
Patent: PROCESO PARA LA PREPARACIÓN DE 4-{4[({[4-CLORO-3-(TRIFLUOROMETILO)-FENILO] AMINO} CARBONILO) AMINO]-3-FLUOROFENOXI}-N-METILPIRIDINO-2-CARBOXAMIDA, SUS SALES Y MONOHIDRATO
Estimated Expiration: ⤷  Sign Up

Croatia

Patent: 0150885
Estimated Expiration: ⤷  Sign Up

Cuba

Patent: 123
Patent: PROCEDIMIENTO PARA LA PREPARACIÓN DE 4-{ 4-[({[4-CLORO-3-(TRIFLUOROMETIL)FENIL]AMINO}CARBONIL)AMINO]-3-FLUOROFENIXI}-N-METILPIRIDINA-2-CARBOXAMIDA Y SU MONOHIDRATO
Estimated Expiration: ⤷  Sign Up

Patent: 120147
Patent: PROCEDIMIENTO PARA LA PREPARACIÓN DE 4-{ 4-[({[4-CLORO-3-(TRIFLUOROMETIL)FENIL]AMINO}CARBONIL)AMINO]-3-FLUOROFENIXI}-N-METILPIRIDINA-2-CARBOXAMIDA Y SU MONOHIDRATO
Estimated Expiration: ⤷  Sign Up

Patent: 140060
Patent: 4-{4-[({[ 4- CLORO-3-( TRIFLUOROMETIL) FENIL] AMINO} CARBONIL) AMINO]-3- FLUOROFENOXI}-N-METILPIRIDINA-2- CARBOXAMIDA Y SU MONOHIDRATO
Estimated Expiration: ⤷  Sign Up

Denmark

Patent: 58448
Estimated Expiration: ⤷  Sign Up

Dominican Republic

Patent: 012000268
Patent: PROCEDIMIENTO PARA LA PREPARACION DE 4-{4-[({[4-CLORO-3-(TRIFLUOROMETIL) FENIL]ANIMO}CARBONIL)AMINO]-3-FLUOROFENOXI}-N-METILPIRIDINA-2-CARBOXAMIDA, SUS SALES Y SU MONOHIDRATO
Estimated Expiration: ⤷  Sign Up

Patent: 016000285
Patent: PROCEDIMIENTO PARA LA PREPARACIÓN DE 4-­{4-­[({[4-­CLORO-­3-­(TRIFLUOROMETIL)FENIL]AMINO}CARBONIL)AMINO]-­3-­FLUOROFENOXI}-­N-­METILPIRIDINA-­2-­CARBOXAMIDA, SUS SALES Y SU MONOHIDRATO
Estimated Expiration: ⤷  Sign Up

Ecuador

Patent: 12012234
Patent: PROCEDIMIENTO
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 58448
Patent: PROCÉDÉ DE PRÉPARATION DE 4-{4-[({[4-CHLORO-3-(TRIFLUOROMÉTHYL)-PHÉNYL]AMINO}CARBONYL)AMINO]-3-FLUOROPHÉNOXY}-N-MÉTHYLPYRIDINE-2-CARBOXAMIDE, SES SELS ET SON MONOHYDRATE (PROCESS FOR THE PREPARATION OF 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)-PHENYL]AMINO}CARBONYL)AMINO]-3-FLUOROPHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE, ITS SALTS AND MONOHYDRATE)
Estimated Expiration: ⤷  Sign Up

Guatemala

Patent: 1200280
Patent: PROCEDIMIENTO
Estimated Expiration: ⤷  Sign Up

Hong Kong

Patent: 00831
Estimated Expiration: ⤷  Sign Up

Hungary

Patent: 26821
Estimated Expiration: ⤷  Sign Up

Israel

Patent: 2348
Patent: תהליך להכנת 4-{4-[({[4--כלורו-3-(טריפלואורומתיל)-פניל]אמינו}קרבוניל)אמינו]-3-פלואורופנוקסי}-n-מתילפירידין-2-קרבוקסאמיד, מלחיו ומונוהידראט שלו (Process for the preparation of 4- {4-[({[4 -chloro-3 -(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorophenoxy}-n-methylpyridine-2-carboxamide, its salts and monohydrate)
Estimated Expiration: ⤷  Sign Up

Patent: 3119
Patent: 4-{4[({[4-כלורו-3-(טריפלואורוצתיל) פניל]אמינו}קרבוניל)אמינו]-3-פלואורופנוקסי}-n-מתילפירידין-2-קרבוקסאמיד, המלחים ומונוהידרט שלו ותכשירים הכוללים אותו (4-{4-[({[4-chloro-3-(trifluoromethyl)lphenyl]amino}carbonyl)amino]-3-fluorophenoxy}-n-methylpyridine-2-carboxamide, its salts and monohydrate and compositions comprising the same)
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 34182
Estimated Expiration: ⤷  Sign Up

Patent: 13523851
Estimated Expiration: ⤷  Sign Up

Jordan

Patent: 58
Patent: عملية تحضير 4- {4 - [({[4-كلورو-3- (ترايفلوروميثيل) -فينيل] أمينو} الكربونيل)أمينو]-3-فلوروفينوكسي}- } -N-ميثلبريدين-2-كربوكساميد، وملح ومونوهيدرات منه (PROCESS FOR THE PREPARATION OF 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)-PHENYL] AMINO}CARBONYL)AMINO]-3-FLUOROPHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE, ITS SALTS AND MONOHYDRATE)
Estimated Expiration: ⤷  Sign Up

Malaysia

Patent: 2359
Patent: PROCESS FOR THE PREPARATION OF 4- {4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)-PHENYL]AMINO}CARBONYL)AMINO]-3-FLUOROPHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE,ITS SALTS AND MONOHYDRATE
Estimated Expiration: ⤷  Sign Up

Patent: 7066
Patent: PROCESS FOR THE PREPARATION OF 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)-PHENYL]AMINO}CARBONYL)AMINO]-3-FLUOROPHENOXY}-N-METHYLPRIDINE-2-CARBOXAMIDE, ITS SALTS AND MONOHYDRATE
Estimated Expiration: ⤷  Sign Up

Mexico

Patent: 12011734
Patent: PROCEDIMIENTO PARA LA PREPARACION DE 4-{4-[({[4-CLORO-3-(TRIFLUORO METIL)FENIL]AMINO}CARBONIL)AMINO]-3-FLUOROFENOXI}-N-METILPIRIDINA -2-CARBOXAMIDA, SUSU SALES Y SU MONOHIDRATO. (PROCESS FOR THE PREPARATION OF 4- {4-[({[4 -CHLORO-3 -(TRIFLUOROMETHYL)-PHENYL]AMINO}CARBONYL)AMINO]-3-FLUOROPHENOXY }-N-METHYLPYRIDINE-2-CARBOXAMIDE, ITS SALTS AND MONOHYDRATE.)
Estimated Expiration: ⤷  Sign Up

Morocco

Patent: 156
Patent: PROCÉDÉDEPRÉPARATIONDE 4-{4-[({[4-CHLORO-3-(TRIFLUOROMÉTHYL)-PHÉNYL]AMINO}CARBONYL)AMINO]-3-FLUOROPHÉNOXY}-N-ÉTHYLPYRIDINE
Estimated Expiration: ⤷  Sign Up

New Zealand

Patent: 2997
Patent: Process for the preparation of 4- { 4-[({ [4 -chloro-3 -(trifluoromethyl)-phenyl]amino} carbonyl)amino]-3-fluorophenoxy} -n-methylpyridine-2-carboxamide, its salts and monohydrate
Estimated Expiration: ⤷  Sign Up

Peru

Patent: 130181
Patent: PROCEDIMIENTO PARA LA PREPARACION DE 4-{4-[({[4-CLORO-3-(TRIFLUOROMETIL)FENIL]AMINO}CARBONIL)AMINO]-3-FLUOROFENOXI}-N-METILPIRIDINA-2-CARBOXAMIDA, SUS SALES Y SU MONOHIDRATO
Estimated Expiration: ⤷  Sign Up

Patent: 160838
Patent: PROCEDIMIENTO PARA LA PREPARACION DE 4-{4-[({[4-CLORO-3-(TRIFLUOROMETIL)FENIL]AMINO}CARBONIL)AMINO]-3-FLUOROFENOXI}-N-METILPIRIDINA-2-CARBOXAMIDA, SUS SALES Y SU MONOHIDRATO
Estimated Expiration: ⤷  Sign Up

Poland

Patent: 58448
Estimated Expiration: ⤷  Sign Up

Portugal

Patent: 58448
Estimated Expiration: ⤷  Sign Up

Russian Federation

Patent: 81585
Patent: СПОСОБ ПОЛУЧЕНИЯ 4-{4-[({[4-ХЛОР-3-(ТРИФТОРМЕТИЛ) ФЕНИЛ] АМИНО}-КАРБОНИЛ) АМИНО]-3-ФТОРФЕНОКСИ}-N-МЕТИЛПИРИДИН-2-КАРБОКСАМИДА, ЕГО СОЛЕЙ И МОНОГИДРАТА (METHOD OF PRODUCING 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL) PHENYL] AMINO} -CARBONYL) AMINO]-3-FLUOROPHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE, SALTS AND MONOHYDRATE THEREOF)
Estimated Expiration: ⤷  Sign Up

Patent: 12148386
Patent: СПОСОБ ПОЛУЧЕНИЯ 4-{4-[({[4-ХЛОР-3-(ТРИФТОРМЕТИЛ) ФЕНИЛ] АМИНО}-КАРБОНИЛ) АМИНО]-3-ФТОРФЕНОКСИ}-N-МЕТИЛПИРИДИН-2-КАРБОКСАМИДА, ЕГО СОЛЕЙ И МОНОГИДРАТА
Estimated Expiration: ⤷  Sign Up

Serbia

Patent: 219
Patent: PROCES ZA PRIPREMU 4-{4-[({[4-HLORO-3-(TRIFLUOROMETIL)-FENIL]AMINO}KARBONIL)AMINO]-3-FLUOROFENOKSI}-N-METILPIRIDIN-2-KARBOKSAMIDA, NJEGOVIH SOLI I NJEGOVOG MONOHIDRATA (PROCESS FOR THE PREPARATION OF 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)-PHENYL]AMINO}CARBONYL)AMINO]-3-FLUOROPHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE, ITS SALTS AND MONOHYDRATE)
Estimated Expiration: ⤷  Sign Up

Singapore

Patent: 4172
Patent: PROCESS FOR THE PREPARATION OF 4- {4-[({[4 -CHLORO-3 -(TRIFLUOROMETHYL)-PHENYL]AMINO}CARBONYL)AMINO]-3-FLUOROPHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE, ITS SALTS AND MONOHYDRATE
Estimated Expiration: ⤷  Sign Up

Patent: 201501221U
Patent: PROCESS FOR THE PREPARATION OF 4- {4-[({[4 -CHLORO-3 -(TRIFLUOROMETHYL)-PHENYL]AMINO}CARBONYL)AMINO]-3-FLUOROPHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE, ITS SALTS AND MONOHYDRATE
Estimated Expiration: ⤷  Sign Up

Slovenia

Patent: 58448
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 1800041
Estimated Expiration: ⤷  Sign Up

Patent: 130061670
Patent: PROCESS FOR THE PREPARATION OF 4- {4- [ ( { [4-CHLORO-3- (TRIFLUOROMETHYL) -PHENYL]AMINO} CARBONYL) AMINO]-3-FLUOROPHENOXY} -N-METHYLPYRIDINE-2-CARBOXAMIDE, ITS SALTS AND MONOHYDRATE
Estimated Expiration: ⤷  Sign Up

Patent: 170129276
Patent: 4―{4―[({[4-클로로―3―(트리플루오로메틸)―페닐]아미노}카르보닐)아미노]―3―플루오로페녹시}―N―메틸피리딘―2―카르복스아미드, 그의 염 및 일수화물의 제조 방법 (- PROCESS FOR THE PREPARATION OF 4-4-4-CHLORO-3-TRIFLUOROMETHYL-PHENYL]AMINOCARBONYLAMINO-3-FLUOROPHENOXY-N-METHYLPYRIDINE-2-CARBOXAMIDE ITS SALTS AND MONOHYDRATE)
Estimated Expiration: ⤷  Sign Up

Spain

Patent: 42610
Estimated Expiration: ⤷  Sign Up

Taiwan

Patent: 75992
Estimated Expiration: ⤷  Sign Up

Patent: 39951
Estimated Expiration: ⤷  Sign Up

Patent: 1204356
Patent: Process
Estimated Expiration: ⤷  Sign Up

Patent: 1509415
Patent: Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorophenoxy}-N-methylpyridine-2-carboxamide, its salts and monohydrate
Estimated Expiration: ⤷  Sign Up

Tunisia

Patent: 12000492
Patent: PROCESS FOR THE PREPARATION OF 4- {4-[({[4 -CHLORO-3 -(TRIFLUOROMETHYL)-PHENYL]AMINO}CARBONYL)AMINO]-3-FLUOROPHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE, ITS SALTS AND MONOHYDRATE
Estimated Expiration: ⤷  Sign Up

Ukraine

Patent: 0613
Patent: СПОСІБ ОДЕРЖАННЯ 4-{4-[({[4-ХЛОР-3-(ТРИФТОРМЕТИЛ)ФЕНІЛ]АМІНО}КАРБОНІЛ)АМІНО]-3-ФТОРФЕНОКСИ}-N-МЕТИЛПІРИДИН-2-КАРБОКСАМІДУ, ЙОГО СОЛЕЙ І МОНОГІДРАТУ (PROCESS FOR PREPARING 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)-PHENYL]AMINO}CARBONYL)AMINO]-3-FLUOROPHENOXY}-N-METHYLPYRIDINE-2-CARBOXARNIDE, ITS SALTS AND MONOHYDRATE)
Estimated Expiration: ⤷  Sign Up

Uruguay

Patent: 290
Patent: PROCEDIMIENTO PARA PREPARAR 4-{4-[({[4-CLORO-3-(TRIFLUOROMETIL)FENIL]AMINO}CARBONIL)AMINO]-3-FLUOROFENOXI}N-METILPIRIDIN-2-CARBOXAMIDA, SUS SALES Y MONOHIDRATO
Estimated Expiration: ⤷  Sign Up

Patent: 590
Patent: PROCEDIMIENTO PARA PREPARAR 4-{4-[({[4-CLORO-3- (TRIFLUOROMETIL)FENIL]AMINO}CARBONIL)AMINO]-3-FLUOROFENOXI}N- METILPIRIDIN-2-CARBOXAMIDA, MONOHIDRATO Y COMPOSICIONES QUE LO COMPRENDEN
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering STIVARGA around the world.

Country Patent Number Title Estimated Expiration
Israel 144144 ⤷  Sign Up
Russian Federation 2009117388 МОНОГИДРАТ 4-[4-({[4-ХЛОР-3-(ТРИФТОРМЕТИЛ)ФЕНИЛ]КАРБАМОИЛ})АМИНО)-3-ФТОРФЕНОКСИ]-N-МЕТИЛПИРИДИН-2-КАРБОКСАМИДА ⤷  Sign Up
Croatia P20010580 OMEGA-KARBOKSIARIL SUPSTITUIRANE DIFENILNE UREE KAO INHIBITORI RAF KINAZ (OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS) ⤷  Sign Up
South Korea 101139557 ⤷  Sign Up
China 100522934 ⤷  Sign Up
Mexico 2007014726 TRATAMIENTO COMBINADO QUE COMPRENDE UN COMPUESTO DIARILUREA Y UNA PI3, AKT CINASA O INHIBIDORES MTOR (RAPAMICINA) PARA TRATAMIENTO DE CANCER. (COMBINATION THERAPY COMPRISING A DIARYL UREA COMPOUND AND A PI3, AKT KINASE OR MTOR INHIBITORS (RAPAMYCINS) FOR CANCER TREATMENT.) ⤷  Sign Up
Chile 2007002930 UN COMPUESTO 4-[4-({[4-CLORO-3-(TRIFLUOROMETIL)FENIL]CARBAMOIL}AMINO)-3-FLUOROFENOXI]-N-METILPIRIDIN-2-CARBOXAMIDA MONOHIDRATADO; PROCESO DE PREPARACION; COMPOSICION Y COMBINACION FARMACEUTICA; Y USO PARA EL TRATAMIENTO DE TRASTORNOS HIPERPROLIFERATI ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for STIVARGA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1663978 475 Finland ⤷  Sign Up
1663978 56/2013 Austria ⤷  Sign Up PRODUCT NAME: REGORAFENIB UND SEINE SALZE; REGISTRATION NO/DATE: EU/1/13/858 (MITTEILUNG) 20130829
1140840 PA2006008 Lithuania ⤷  Sign Up PRODUCT NAME: SORAFENIBAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/06/342/001 20060719
1140840 300242 Netherlands ⤷  Sign Up
1663978 CA 2013 00056 Denmark ⤷  Sign Up PRODUCT NAME: REGORAFENIB OG SALTE DERAF; REG. NO/DATE: EU/1/13/858 20130826
1140840 SPC 031/2006 Ireland ⤷  Sign Up SPC 031/2006: 20070528, EXPIRES: 20210718
1140840 06C0034 France ⤷  Sign Up PRODUCT NAME: SORAFENIB TOSYLATE, ET AUTRES SELS PHARMACEUTIQUEMENT ACCEPTABLES DE SORAFENIB; REGISTRATION NO/DATE IN FRANCE: EU/1/06/342/001 DU 20060719; REGISTRATION NO/DATE AT EEC: EU/1/06/342/001 DU 20060719
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.